J. Stigt

Maximal expiratory and inspiratory flow-volume curves in Parkinson's disease.

J. Bogaard, A. Hovestadt, J. Meerwaldt, 1989, The American review of respiratory disease.

University of Groningen A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

J. Stigt, H. Groen, B. Biesma, 2004 .

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).

G. Giaccone, E. Smit, M. Krzakowski, 2003, European Journal of Cancer.

127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

H. Gietema, S. Keek, H. Woodruff, 2022, Annals of Oncology.

Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

A. Dingemans, C. Pitz, E. de Vries, 2021, European Journal of Cancer.

Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.

O. Dalesio, H. Groen, J. Slaets, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary function in Parkinson's disease.

J. Bogaard, A. Hovestadt, J. Meerwaldt, 1989, Journal of neurology, neurosurgery, and psychiatry.

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

E. D. de Vries, A. Dingemans, C. Pitz, 2020, European Journal of Cancer.

A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

H. Groen, E. Smit, J. Aerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.